Oligopeptide and application thereof in preparation of muscle attenuation delaying product
Patent Information
- Application Number
- CN202411416109.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-11
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-10-11
AI Technical Summary
Current methods to delay muscle attenuation, characterized by progressive muscle mass reduction and decreased function, are limited, primarily relying on high-quality protein supplementation and exercise, and there is a need for more effective interventions.
Development of oligopeptides, specifically tetrapeptides and tripeptides with amino acid sequences LWPF and LPGF, synthesized via solid phase synthesis, which are combined to form oligopeptide compositions for use in products to delay muscle attenuation and improve muscle motility.
The synthesized oligopeptides effectively delay muscle attenuation, maintain muscle fiber structure, and enhance muscle mobility without side effects, as demonstrated by experiments on Caenorhabditis elegans, indicating their potential in various products.
Smart Images

Figure CN119060126A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, in particular to an oligopeptide and application thereof in the preparation of a product for delaying muscle attenuation. Background Art
[0002] Muscle attenuation is a degenerative syndrome characterized by progressive reduction of muscle mass, decreased muscle strength, and decreased physiological function of muscles with aging. Muscle attenuation can cause a series of serious health problems, such as falls, fractures, incapacity, and disability; it can also significantly increase infection rates, hospitalization rates, and mortality rates, forming a causal chain of high mortality rates in the elderly. In addition, muscle attenuation increases the risk of various chronic diseases, such as osteoporosis, chronic enteritis, diabetes, chronic obstructive pulmonary disease, and tumors. At present, the prevalence of sarcopenia is very high. According to statistics, the incidence rate in the elderly aged 60 to 70 is 5% to 13%, and the incidence rate in the elderly over 80 is as high as 11% to 50%. The older the age, the higher the incidence rate. With the aging of society, the prevalence of sarcopenia will show a significant upward trend, and it will become a major public health and socioeconomic problem that threatens the health of the whole people, reduces the quality of life, and consumes medical resources.
[0003] However, the current technical means to delay muscle attenuation are still relatively limited. They are mainly based on supplementing high-quality protein and exercise. Oligopeptides are a type of peptide composed of 2 to 10 amino acids. Different amino acid compositions have different biological activities. Therefore, the present invention has developed oligopeptides with the effect of delaying muscle attenuation through a large number of experiments. Summary of the invention
[0004] The purpose of the present invention is to overcome the shortcomings of the prior art and provide an oligopeptide and its application in the preparation of a product for delaying muscle attenuation.
[0005] To achieve the above object, the technical solution adopted by the present invention is:
[0006] In a first aspect, the present invention provides an oligopeptide, wherein the oligopeptide comprises a tetrapeptide and / or a tripeptide; the amino acid sequence of the tetrapeptide is LWPF and / or LPGF; the amino acid sequence of the tripeptide is FEP.
[0007] The present invention can obtain three oligopeptides with different amino acid sequences through solid phase synthesis, and experiments have confirmed that the obtained three oligopeptides all have the effect of improving muscle attenuation.
[0008] As a preferred embodiment of the oligopeptide of the present invention, the oligopeptide is mainly synthesized by solid phase synthesis.
[0009] In the second aspect, the present invention provides an oligopeptide composition having the effect of delaying muscle attenuation, the oligopeptide composition comprising at least two of oligopeptide I, oligopeptide II and oligopeptide III; the amino acid sequences of oligopeptide I, oligopeptide II and oligopeptide III are independently selected from at least one of LWPF, LPGF and FEP. In addition to the oligopeptide of the present invention having the effect of delaying muscle attenuation by a single oligopeptide, a combination of two or more oligopeptides also has the effect of delaying muscle attenuation.
[0010] As a preferred embodiment of the oligopeptide composition of the present invention, the oligopeptide I, oligopeptide II and oligopeptide III are mainly synthesized by solid phase synthesis.
[0011] In a third aspect, the present invention provides the use of the above-mentioned oligopeptide or oligopeptide composition in the preparation of a product for delaying muscle attenuation.
[0012] In a fourth aspect, the present invention provides the use of the above-mentioned oligopeptide or oligopeptide composition in the preparation of a product for improving muscle motility.
[0013] As a preferred embodiment of the application of the present invention, the products include medicines, foods, health products, cosmetics and biological products.
[0014] In a fifth aspect, the present invention provides a composition for delaying muscle attenuation, comprising the above-mentioned oligopeptide or oligopeptide composition.
[0015] As a preferred embodiment of the composition for delaying muscle attenuation of the present invention, the composition for delaying muscle attenuation further includes auxiliary materials.
[0016] As a preferred embodiment of the composition for delaying muscle attenuation of the present invention, the auxiliary materials include at least one of flavoring agents, adhesives, lubricants, disintegrants, antioxidants, stabilizers, thickeners and fillers.
[0017] Compared with the prior art, the present invention has the following beneficial effects:
[0018] The present invention can obtain three oligopeptides with different amino acid sequences through solid phase synthesis. Experiments have confirmed that the three oligopeptides obtained all have the effect of improving muscle attenuation, and have the advantages of being safe, usable for a long time, and having no side effects. They can be applied to products for improving muscle attenuation and its related symptoms. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 The liquid chromatograms of different oligopeptides in Example 1 of the present invention, wherein Figure A is oligopeptide LWPF, Figure B is oligopeptide LPGF, and Figure C is oligopeptide FEP;
[0020] Figure 2 The mass spectrum of the oligopeptide LWPF in Example 1 of the present invention;
[0021] Figure 3 The mass spectrum of the oligopeptide LPGF in Example 1 of the present invention;
[0022] Figure 4 The mass spectrum of the oligopeptide FEP in Example 1 of the present invention;
[0023] Figure 5 The effects of different treatments on nematode muscle in Example 2 of the present invention;
[0024] Figure 6 The effects of different samples on the pharyngeal pumping times of nematodes in Example 3 of the present invention;
[0025] Figure 7 This is the effect of different samples in Effect Example 3 of the present invention on the number of nematode body swings. DETAILED DESCRIPTION
[0026] In order to better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments.
[0027] Unless otherwise specified, other materials, reagents, etc. used in the examples can be obtained from commercial sources.
[0028] Escherichia coli NA22 and Caenorhabditis elegans N2 were purchased from the Caenorhabditis Genetics Center at the University of Minnesota.
[0029] The techniques not described in detail in the following embodiments, comparative examples and effect examples are all commonly used techniques in the art. Please refer to "Molecular Biology Experiment Manual" (Ma Wenli, People's Military Medical Publishing House), "Molecular Biology Experiment (Second Edition)" (Zhejiang University Press), and "Cell Biology Experiment" (Yang Hongbing, Hou Lixia, Zhang Yuxi, Higher Education Press).
[0030] In the following embodiments and effect examples, "V" refers to valine (Val), "P" refers to proline (Pro), "G" refers to glycine (Gly), "H" refers to histidine (His), "R" refers to arginine (Arg), "K" refers to lysine (Lys), "I" refers to isoleucine (Ile), "F" refers to phenylalanine (Phe), "L" refers to leucine (Leu), "W" refers to tryptophan (Trp), "A" refers to alanine (Ala), "M" refers to methionine (Met), "C" refers to cysteine (Cys), "N" refers to asparagine (Asn), "S" refers to serine (Ser), "Q" refers to glutamine (Gln), "Y" refers to tyrosine (Tyr), "D" refers to aspartic acid (Asp), "E" refers to glutamic acid (Glu), and "T" refers to threonine (Thr).
[0031] In the following examples and effect examples, LWPF refers to the oligopeptide Leu-Trp-Pro-Phe, LPGF refers to the oligopeptide Leu-Pro-Gly-Phe, and FEP refers to the oligopeptide Phe-Glu-Pro.
[0032] Example 1
[0033] This embodiment provides an oligopeptide, which is prepared by the following steps:
[0034] 1. Weigh 3 g of Rink Amide Resin (substitution degree 0.3 mmol / g) into a 150 mL reactor, soak it in 50 mL of dichloromethane (DCM) for 2 h, wash the resin with 3 times the volume of the resin in nitrogen-dimethylformamide (DMF), and then drain it. Repeat this four times, and drain the resin for later use;
[0035] 2. Add a certain amount of 20% v / v piperidine (solvent is DMF) to the reactor, shake it on a decolorizing shaker for 20 minutes to remove the Fmoc protecting group on the resin. After removing the protecting group, wash it four times with DMF 3 times the volume of the resin, and then drain it; take a small amount of resin and test it with the ninhydrin (nine-well hydrated ninhydrin) method (two drops of test A and test B, react at 100°C for 1 minute). The resin has color, indicating that the deprotection group is successful;
[0036] 3. Weigh an appropriate amount of the first amino acid at the C-terminus and an appropriate amount of 1-hydroxy-benzotriazole (HOBT) into a 50 mL centrifuge tube, add 20 mL of DMF to dissolve them, then add 3 mL of N, N-diisopropylcarbodiimide (DIC) and shake for 1 min. After the solution is clarified, add it to the reactor, then place the reactor in a shaker at 30 ° C for 2 h, cap it with a certain amount of acetic anhydride (acetic anhydride: N, N-diisopropylethylamine: DCM = 1:1:2) for 0.5 h, then wash it four times with 3 times the volume of the resin in DMF, and drain it for use;
[0037] 4. Remove the Fmoc protecting group on the resin in the reactor according to the method of step B2;
[0038] 5. Weigh an appropriate amount of the second amino acid and an appropriate amount of HOBT into a 50mL centrifuge tube, add 25mL of DMF to dissolve it, then add 2.5mL of DIC and shake for 1min. After the solution is clarified, add it to the reactor, and then place the reactor in a shaker at 30°C for 1h. Take a small amount of resin for detection and use the ninhydrin method to detect (two drops of test A and test B, 100°C for 1min). If the resin is colorless, it means that the reaction is complete; if the resin has color, it means that the condensation is incomplete, and the reaction is continued; after the reaction is complete, wash the resin four times with DMF, then drain it, add a certain amount of 20% v / v piperidine (solvent is DMF) to the reactor, and shake it on a decolorization shaker for 20min to remove the Fmoc protecting group on the resin. After deprotection, wash it four times with DMF, then drain it to detect whether the protection is removed;
[0039] 6. Connect the following amino acids in sequence according to steps B1-B5. After the last amino acid is connected, remove the protection, wash four times with DMF, then drain the resin with methanol, and then cut the polypeptide from the resin with 95 cutting solution (trifluoroacetic acid: 1,2-dithiol: 3-isopropylsilane: water = 95:2:2:1) (add 10 mL of cutting solution per gram of resin), and centrifuge and precipitate four times with ice ether (cutting solution: ether = 1:9), and separate and purify by HPLC to obtain high-purity oligopeptides.
[0040] According to the above method, polypeptides with amino acid sequences of LWPF, LPGF and FEP can be synthesized respectively.
[0041] Effect Example 1
[0042] The oligopeptide obtained in Example 1 was characterized by HPLC-MS / MS, and the specific scheme is as follows:
[0043] A Waters 2695-ZQ2000 single quadrupole liquid spectrometer (Waters, USA) was used to separate and detect the samples, and an ODS-SP column (4.6×250 mm×5 μm) (Shimadzu, Japan) was used.
[0044] The mobile phase consisted of 0.1% (v / v) trifluoroacetic acid aqueous solution (A) and 0.1% (v / v) trifluoroacetic acid acetonitrile (B), the elution method was 0-25.00min 10%-70% B, 25.01-30.00min 100% B, flow rate 1mL / min, injection volume 30μL, column temperature: 40°C, the percentage of the above mobile phase means volume percentage, volume of mobile phase B / total volume of mobile phase A and mobile phase B.
[0045] Mass spectrometry detection method: scanning cycle 0.1S, ESI ion source temperature 100℃, positive ion mode, spray voltage 3000V, scanning range 300-1999Da, identification results are shown in Table 1 and Figure 1-4 .
[0046] Table 1 Identification results of oligopeptides
[0047]
[0048] As shown in Table 1 and Figure 1-4 As shown, the amino acid sequences of the oligopeptides identified by HPLC-MS / MS technology in the present invention are LWPF, LPGF and FEP respectively.
[0049] Effect Example 2
[0050] The efficacy of the oligopeptides (LWPF, LPGF and FEP) obtained in Example 1 in delaying muscle loss and protecting muscle tissue was evaluated by using Caenorhabditis elegans N2. The specific scheme is as follows:
[0051] The experiment was conducted with reference to the following literature: Zhang Huijie, Effects and mechanisms of wild chrysanthemum lactone in delaying aging and treating sarcopenia [D] Nanchang University 2022-5-23.
[0052] RW1596 nematodes were used, and the worm density was adjusted to about 1 / 10 μL with SM culture medium, and then transferred to a 24-well plate (1000 μL / well). 100 μL of NA22 was added to each well of the 24-well plate and the drug was administered at 20°C until the 15th day of adulthood. The Caenorhabditis elegans was washed into a 5 mL centrifuge tube, and the supernatant was discarded after sedimentation. The washing was repeated 2-3 times, and 20 μL was aspirated onto a glass slide. A drop of vegetable oil was added to cover the body of the nematode to prevent the nematode from dehydrating. Subsequently, the nematodes were inverted and photographed under a fluorescence microscope at a magnification to observe the changes in the sarcomere structure of Caenorhabditis elegans. The experimental groups were set as a blank group, a positive drug group, and a sample group. The positive drug group was 500 μg / mL of Ginkgo biloba extract, and the sample groups were 10 mg / mL of the oligopeptides (LWPF, LPGF, and FEP) obtained in Example 1. The results are shown in Figure 5 .
[0053] like Figure 5 As shown in the figure, the straight lines of sarcomeres in the body wall muscles of C. elegans in the blank control group were severely broken, and the green straight lines were no longer parallel. However, compared with the blank group, the muscle lines of the oligopeptide sample group showed a complete and neatly arranged network, and each body wall muscle showed multiple green parallel straight lines. This shows that the oligopeptides LWPF, LPGF and FEP have good effects in delaying muscle loss and maintaining the good structure of muscle fibers.
[0054] Effect Example 3
[0055] The effect of improving muscle motor function of the oligopeptides (LWPF, LPGF and FEP) obtained in Example 1 was evaluated by using Caenorhabditis elegans N2. The specific scheme is as follows:
[0056] Refer to the following literature to conduct experiments to improve muscle motor function testing:
[0057] Dhondt I,Verschuuren C, A.Prediction of biological age bymorphological staging of sarcopenia in Caenorhabditis elegans.Dis ModelMech.2021Nov 1;14(11):dmm049169.
[0058] Chow DK, Glenn CF, Johnston JL, Goldberg IG, Wolkow CA. Sarcopenia in theCaenorhabditis elegans pharynx correlates with muscle contraction rate overlifespan. Exp Gerontol. 2006Mar;41(3):252-260.
[0059] Caenorhabditis elegans N2 was used. The nematode density was adjusted to about 1 / 10 μL with SM medium and then transferred to a 24-well plate (1000 μL / well). 100 μL of NA22 was added to each well of the 24-well plate and the drug was administered at 20°C. After intervention until the 15th day of adulthood, the test was performed.
[0060] Body swing index detection: Pipette 100 μL of worm liquid and drop it onto a glass slide. Use a pipette tip to spread the worm liquid evenly without overlapping. Place it under a 5X objective lens of a microscope. After standing for 5 minutes, record a 30-second motion video. Open the video and play it at 0.5 times the speed. Track the nematodes in the video and count the number of times they swing their heads.
[0061] Pharyngeal pumping index detection: aspirate 10 μL of worm liquid and drop it onto a glass slide. Place it under a microscope and let it stand for 1 minute. Then record a 30-second pharyngeal pumping video under a 10X objective. Open the video and play it at 0.5 times the speed. Track the nematodes in the video and count the number of pharyngeal pumping of its head.
[0062] The above results can be seen in Figure 6-7 and Table 2.
[0063] The experimental groups were set as blank group, positive drug group, and oligopeptide group, among which the positive drug group was 500 μg / mL of Ginkgo biloba leaf extract and the oligopeptide group was 1 mg / mL.
[0064] Table 2 Statistics of pharyngeal pumping and body swinging times of nematodes in different treatment groups
[0065]
[0066]
[0067] As shown in Table 2 and Figure 6-7 As shown, the number of pharyngeal pumps and body swings of the nematodes in the oligopeptides group was significantly increased compared with that in the blank control group, indicating that the oligopeptides LWPF, LPGF and FEP of the present invention can improve the motor ability of muscles.
[0068] In summary, the oligopeptides and oligopeptide compositions of the present invention can delay muscle loss, maintain a good structure of muscle fibers, and improve muscle mobility, thereby improving muscle attenuation.
[0069] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.
Claims
1. An oligopeptide, characterized in that: The oligopeptide includes a tetrapeptide and / or a tripeptide; the amino acid sequence of the tetrapeptide is LWPF and / or LPGF; the amino acid sequence of the tripeptide is FEP.
2. The oligopeptide according to claim 1, characterized in that The oligopeptide is mainly synthesized by solid phase synthesis method.
3. An oligopeptide composition having the effect of delaying muscle attenuation, characterized in that: The oligopeptide composition comprises at least two of oligopeptide I, oligopeptide II and oligopeptide III; the amino acid sequences of oligopeptide I, oligopeptide II and oligopeptide III are independently selected from at least one of LWPF, LPGF and FEP.
4. The oligopeptide composition according to claim 3, characterized in that The oligopeptide I, oligopeptide II and oligopeptide III are mainly synthesized by solid phase synthesis method.
5. Use of the oligopeptide according to any one of claims 1 to 2 or the oligopeptide composition according to any one of claims 3 to 4 in the preparation of a product for delaying muscle attenuation.
6. Use of the oligopeptide according to any one of claims 1 to 2 or the oligopeptide composition according to any one of claims 3 to 4 in the preparation of a product for improving muscle motility.
7. The use according to claim 5 or 6, characterized in that: The products include medicines, foods, health products, cosmetics and biological products.
8. A composition for delaying muscle attenuation, characterized in that: The method comprises the oligopeptide according to any one of claims 1 to 2 or the oligopeptide composition according to any one of claims 3 to 4.
9. The composition for delaying muscle attenuation according to claim 8, characterized in that: The composition for delaying muscle attenuation further comprises auxiliary materials.
10. The composition for delaying muscle attenuation according to claim 9, characterized in that: The auxiliary materials include at least one of flavoring agents, binders, lubricants, disintegrants, antioxidants, stabilizers, thickeners and fillers.
Citation Information
Patent Citations
Composition for delaying muscle attenuation and preparation method and application thereof
CN115025177A
Application of small-molecule active oligopeptide in preparation of products for improving skeletal muscle dysfunction and / or enhancing skeletal muscle contraction function
CN116350745A
Compositions for promoting local muscle growth, slowing down or preventing local muscle atrophy, and their uses.
TWI649332B
Peptide constructs and well-defined aggregates thereof
US20160228569A1
Cited By
Polypeptide as well as preparation method and application thereof in delaying muscle attenuation
CN122011107A
A polypeptide, its method of production and its use in delaying muscle decline
CN122011107B
